Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6ZF | ISIN: US03528H1095 | Ticker-Symbol: CY71
Tradegate
22.11.24
16:14 Uhr
3,380 Euro
+0,300
+9,74 %
Branche
Bekleidung/Textil
Aktienmarkt
Sonstige
1-Jahres-Chart
ANIXA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ANIXA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,0603,16010:40
3,0203,14022.11.

Aktuelle News zur ANIXA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ANIXA BIOSCIENCES Aktie jetzt für 0€ handeln
FrAnixa rises as board approves Bitcoin as a treasury reserve asset2
FrAnixa Biosciences diversifiziert mit Bitcoin-Investment1
FrAnixa Biosciences diversifies with Bitcoin investment2
MoAnixa Hikes on Tests2
MoAnixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial79Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences...
► Artikel lesen
08.11.Anixa reports progress in breast cancer vaccine trial1
08.11.Anixa verzeichnet Fortschritte bei Brustkrebs-Impfstoff-Studie1
08.11.Anixa Biosciences, Inc.: Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual ...114Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol...
► Artikel lesen
08.11.Anixa Biosciences Inc - 8-K, Current Report-
15.10.Anixa Biosciences, Inc.: Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial105Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/...
► Artikel lesen
30.09.Anixa strebt Genehmigung für wiederholte CAR-T-Dosen in Eierstockkrebs-Studie an-
24.09.Anixa Biosciences, Inc.: Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine436Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the...
► Artikel lesen
06.09.Anixa Biosciences Inc - 10-Q, Quarterly Report1
23.07.Anixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy335IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- Anixa Biosciences...
► Artikel lesen
23.07.EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy1
17.07.Anixa Biosciences, Inc.: Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology112SAN JOSE, Calif., July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
► Artikel lesen
15.07.Anixa Biosciences authorizes $5M share buyback program1
15.07.EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program1
24.06.Anixa Biosciences, Inc.: Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial128This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
► Artikel lesen
04.06.Anixa Biosciences Inc - 10-Q, Quarterly Report1
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1